A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

NCT05495464 EARLY_PHASE1 ACTIVE_NOT_RECRUITING

To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	EARLY_PHASE1
Status	ACTIVE_NOT_RECRUITING
Enrolment	22
Start date	Fri Nov 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Lymphoma
• Mantle Cell Lymphoma

Interventions

• Acalabrutinib
• Rituximab
• Brexucabtagene Autoleucel
• Cyclophosphamide
• Fludarabine Phosphate

Countries

United States